Bristol Myers Squibb– tag –
-
Cell and Gene Therapy Sector Shifts to “Execution Discipline” Amidst Manufacturing Platform Scrutiny and Autoimmune CAR-T Safety Concerns
LucidQuest Ventures USA Overview A recent strategic roundup highlights a critical shift in the cell and gene therapy (CGT) sector from platform expansion to "execution discipline," emphasized by Bristol Myers Squibb's termination of its ... -
Novartis Halts Autoimmune CAR-T Trials After Three Patient Deaths, Sparking Safety Debate
Endpoints News USA Overview Novartis has disclosed the deaths of three patients from immune effector cell-associated hemophagocytic lymphohistiocytosis (IEC-HS) complications in clinical trials of its CAR-T cell therapy, rapcabtagene aut... -
Novartis Halts CAR T-Cell Trials Following Patient Deaths in Experimental Therapy
pharmaphorum USA Overview Novartis has temporarily halted eight clinical trials for its experimental CAR T-cell therapy, rapcabtagene autoleucel (rap-cel), following the deaths of three patients from immune effector cell-associated hemop... -
Bristol Myers Squibb Terminates $380M CAR-T Manufacturing Partnership with Cellares Due to Production Failures for Breyanzi
PharmaLive USA Overview Bristol Myers Squibb (BMS) has ended its $380 million partnership with Cellares, citing Cellares' Cell Shuttle system's failure to meet commercial production requirements for BMS's CAR T-cell immunotherapy, Breyan... -
FDA Grants Accelerated Approval to BMS’s Zenbexus for Multiple Myeloma in Combination with Daratumumab
U.S. Food and Drug Administration (FDA) USA Overview The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's (BMS) Zenbexus (iberdomide), a novel CELMoD (cereblon E3 ligase modulator), for the treatment of multiple myelom... -
FDA Grants Accelerated Approval to BMS’s CELMoD Zenbexus in Quadruple Therapy for Relapsed/Refractory Multiple Myeloma
Drugs.com, FDA.gov USA Overview The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's cereblon E3 ligase modulating agent (CELMoD) Zenbexus (iberdomide) in combination with daratumumab, hyaluronidase-fihj, and dexametha... -
BMS’s First CELMoD Therapy ZENBEXUS™ Receives Accelerated FDA Approval in Combination with Daratumumab for Multiple Myeloma, Including Early Relapse Patients
Bristol Myers Squibb USA Overview The U.S. FDA granted accelerated approval to Bristol Myers Squibb's first Cereblon E3 ligase modulator (CELMoD) therapy, ZENBEXUS™ (iberdomide), in combination with daratumumab, hyaluronidase-fihj, and d... -
Bristol Myers Squibb’s First CELMoD Therapy ZENBEXUS™ (iberdomide) Receives FDA Accelerated Approval in Combination with Daratumumab for Multiple Myeloma Patients with Early Relapse
Bristol Myers Squibb (Press Release) USA Overview Bristol Myers Squibb announced that its innovative CELMoD therapy, ZENBEXUS™ (iberdomide), received accelerated approval from the U.S. FDA for multiple myeloma, in combination with daratu... -
BMS Molecular Glue Mezigdomide Combination Therapy Transforms Oncology: Achieves 52% Reduction in Progression or Death Risk in Phase 3 Multiple Myeloma Trial
PMLiVE Unknown Overview Targeted protein degraders (TPDs), specifically PROTACs and molecular glues, are rapidly advancing in oncology. At ASCO, Bristol Myers Squibb (BMS) announced Phase 3 results showing their molecular glue, Mezigdomi... -
BMS Reveals Promising Clinical Data for Next-Gen Blood Cancer Therapy Mezigdomide
BioPharma Dive USA Overview Bristol Myers Squibb (BMS) unveiled promising new clinical data for mezigdomide, its next-generation blood cancer therapy. This drug is one of two key protein degradation inducers BMS expects to succeed its mu...
12